Business

mass. movers

Agenus slumps as clinical tests disappoint

Glaxo is studying drugs that use a compound from Lexington-based Agenus.

Associated Press/File 2010

Glaxo is studying drugs that use a compound from Lexington-based Agenus.

Advertisement

Agenus Inc. fell sharply after an unsuccessful clinical trial of a cancer treatment that includes its compound that is designed to make drugs more effective. British drug maker GlaxoSmithKline is studying cancer treatments that include Agenus’s SQ-21 Stimulon vaccine adjuvant. Glaxo said an experimental melanoma treatment did not meet its first goal in a mid-stage clinical trial. Glaxo is studying an immune therapy that targets MAGE-A3, an antigen found in various cancers. The therapy includes Agenus’ SQ-21 Stimulon adjuvant, extracted from the bark of an evergreen called Soapbark.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com